Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis

Le Cann, Fabienne, Delehouzé, Claire, Leverrier-Penna, Sabrina, Filliol, Aveline, Comte, Arnaud, Delalande, Olivier, Desban, Nathalie, Baratte, Blandine, Gallais, Isabelle, Piquet-Pellorce, Claire, Faurez, Florence, Bonnet, Marion ORCID: https://orcid.org/0000-0002-7559-2413, Mettey, Yvette, Goekjian, Peter, Samson, Michel, Vandenabeele, Peter, Bach, Stéphane and Dimanche-Boitrel, Marie-Thérèse 2017. Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis. FEBS Journal 284 (18) , pp. 3050-3068. 10.1111/febs.14176

Preview

PDF - Accepted Post-Print Version Download (1MB) | Preview

Abstract

Necroptosis is a regulated form of cell death involved in several disease models including in particular liver diseases. Receptor-interacting protein kinases, RIPK1 and RIPK3, are the main serine/threonine kinases driving this cell death pathway. We screened a noncommercial, kinase-focused chemical library which allowed us to identify Sibiriline as a new inhibitor of necroptosis induced by tumor necrosis factor (TNF) in Fas-associated protein with death domain (FADD)-deficient Jurkat cells. Moreover, Sib inhibits necroptotic cell death induced by various death ligands in human or mouse cells while not protecting from caspase-dependent apoptosis. By using competition binding assay and recombinant kinase assays, we demonstrated that Sib is a rather specific competitive RIPK1 inhibitor. Molecular docking analysis shows that Sib is trapped closed to human RIPK1 adenosine triphosphate-binding site in a relatively hydrophobic pocket locking RIPK1 in an inactive conformation. In agreement with its RIPK1 inhibitory property, Sib inhibits both TNF-induced RIPK1-dependent necroptosis and RIPK1-dependent apoptosis. Finally, Sib protects mice from concanavalin A-induced hepatitis. These results reveal the small-molecule Sib as a new RIPK1 inhibitor potentially of interest for the treatment of immune-dependent hepatitis.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Wiley-Blackwell
ISSN:	1742-464X
Date of First Compliant Deposit:	11 August 2017
Date of Acceptance:	13 July 2017
Last Modified:	06 May 2023 05:45
URI:	https://orca.cardiff.ac.uk/id/eprint/103526

Citation Data

Cited 15 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item